I am currently Project Director and Group Leader at the Department of Fundamental Microbiology of the Faculty of Biology and Medicine (FBM), University of Lausanne.
I have been working in the field of new antimicrobial development since more than 15 years, with a peculiar interest in original pathogen-specific strategies. These should be more respectful than conventional antibiotics both for the patient, because they do not destroy his or her commensal microbiomes, and for the environment because they do not select for global antibiotic resistance. Two of these approaches include bacteriophage therapy (or phage therapy), and phage-lysin therapy.
Dr. Grégory Resch, PhD.